Evaluation of the safety and pharmacokinetic profile of the broad spectrum antiviral lectin Griffithsin.

Griffithsin;Griffithisia sp;GRFT

Christopher Lynn Barton

University:University of Louisville

Department:Pharmacology and Toxicology

关键词: Griffithsin;    Griffithisia sp;    GRFT;   

Others  :  https://ir.library.louisville.edu/cgi/viewcontent.cgi?article=1079&context=etd

美国|英语

来源: The Universite of Louisville's Institutional Repository

【 摘 要 】

Carbohydrate binding agents that target viral envelope glycans are being studied for their potential use as microbicides and antiviral therapeutics. Griffithsin is a lectin originally identified in a red alga Griffithisia sp. Multiple studies have shown that GRFT inhibits HIV-1, Coronaviruses, Hepatitis C, influenza and Ebola virus replication in vitro. This antiviral activity suggests potential uses in chemoprophylaxis and disease treatment. However, safety of GRFT administration has not been extensively studied. In vivo testing--chronic subcutaneous treatment as well as single dose subcutaneous, oral, and intravenous administrations of Griffithsin in Sprague Dawley Rats (Rattus Norvegicus)--was used to assess Griffithsin’s pharmacokinetic properties and to predict whether use of Griffithsin for antiviral treatment might be safe and effective. Based on histological, serological, and biochemical data derived from these experiments, Griffithsin is generally well tolerated. However, protein binding assays revealed interactions with complement and apolipoproteins and calorimetric assays revealed changes in serum thermograms that may require further study.